Hangzhou Valgen Medtech Co., Ltd. Overview
Pro stress-test →Valgen Medtech specializes in the collaboration between hospitals and medical device manufacturers to provide integrated interventional treatment solutions to patients with bicuspid and tricuspid diseases. The company specializes in interventional treatment products and technologies for mitral and tricuspid valve repair within the medical device industry.
Strategic Profile
Pro stress-test →Valgen has applied for more than 600 patents worldwide for fundamental principles, core solutions, and/or key innovations of its products of which 200 of the patents have been granted. Four of its products have passed NMPA's special review for innovative medical devices, and five of its products have been officially marketed. On November 22, 2023, the company and Venus Medtech reached an exclusive strategic marketing cooperation intention in relation to the DragonFly™ Transcatheter Mitral Valve Repair System.
Competitive Landscape
Pro stress-test →Venus Medtech is a leading enterprise in the field of minimally-invasive intervention for heart valves in China, serving as both a competitor and strategic partner. Other structural heart disease device manufacturers like Abbott (Mitraclip), Edwards Lifesciences, and Boston Scientific compete in the broader transcatheter valve repair market, though primarily outside China. The Chinese market for minimally-invasive valve repair remains underpenetrated compared to developed markets.
Industry Context
Hangzhou Valgen Medtech Co., Ltd. operates in Transcatheter mitral valve repair devices.
Key facts
Founded: 2015 · Headquarters: Hangzhou, China · Employees: 280+